Condition
Bortezomib
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Unknown4
Clinical Trials (4)
Showing 4 of 4 trials
NCT05982756Phase 1UnknownPrimary
Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML
NCT05383547Not ApplicableUnknownPrimary
Bortezomib for Treating Glomerular Diseases
NCT04678089Unknown
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
NCT02027220Phase 2Unknown
Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma
Showing all 4 trials